Consult trial design [Design Issues]

posted by libaiyi – China, 2024-07-03 11:12 (712 d 09:31 ago) – Posting: # 24058
Views: 2,547

Hello everyone, I have two questions. The first question is that I would like to know if ANDA only includes BE studies, and if the endpoints for BE studies can be efficacy endpoints instead of PK parameters.

The second question is about a pediatric anesthetic drug that we have applied NDA in China, and we now want to apply NDA in Europe and the United States. The drug has already been approved for use in adults in Europe and the United States. Can we apply for market approval with just a pediatric bridging study, or we need to collect data from both adults and a small number of children in Europe and the United States and conduct a regular study design? Is there any reference study or paper available?

Thank you very much!

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,570 registered users;
98 visitors (0 registered, 98 guests [including 11 identified bots]).
Forum time: 20:44 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5